[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339958-105":3,"doc-detail-339958-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","advances-in-personalized-oncology","Advances in Personalized Oncology","","Advances in next-generation sequencing (NGS) is transforming cancer care by shifting from organ-based protocols toward precision medicine. Targeted therapies provide new options, while companion diagnostics help select treatments matched to molecular alterations detected by NGS. Translating the growing list of genetic mutations into actionable clinical decisions remains difficult. Therapy selection with multiple mutations requires sound clinical judgment supported by high-quality genomic testing emphasizing actionable variants. Molecular tumor boards may integrate genomic evidence into trials, enabling refined personalized strategies and improved patient outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/advances-in-personalized-oncology/339958/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/advances-in-personalized-oncology/339958.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How has next-generation sequencing changed cancer treatment?","Question",{"text":63,"@type":64},"NGS enables identification of cancer-driving mutations and supports precision medicine by guiding targeted therapy selection rather than relying only on conventional organ-specific approaches.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role do companion diagnostics play in targeted therapy?",{"text":68,"@type":64},"Companion diagnostics align therapeutic decisions with specific molecular changes identified through NGS, helping ensure that treatment matches actionable genetic alterations.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is interpreting genetic mutation catalogs clinically challenging?",{"text":72,"@type":64},"Clinical interpretation is difficult because the catalog of genetic mutations is rapidly expanding and patients may carry multiple mutations, requiring careful judgment and quality-focused testing.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339958,1790212445,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2",8,"cancers   \nReview  \nAdvances in Personalized Oncology  \nHiba Mechahougui 1, James Gutmans 1, Gina Colarusso 1, Roumaïssa Gouasmi 2 and Alex Friedlaender 3, *  \nCitation: Mechahougui, H.; Gutmans, J.; Colarusso, G.; Gouasmi, R.; Friedlaender, A. Advances in Personalized Oncology. Cancers 2024, 16, 2862. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers16162862  \nAcademic Editor: Gabriella D’Orazi  \nReceived: 16 June 2024  \nRevised: 12 August 2024  \nAccepted: 14 August 2024  \nPublished: 16 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Oncology Department, Geneva University Hospital (HUG), 1205 Geneva, Switzerland;  \nhiba.mechahougui@hcuge.ch (H.M.)  \n2 Cancer Research Center of Lyon, CNRS UMR5286, Inserm U1052, University of Lyon, 69100 Lyon, France  \n3 Clinique Générale Beaulieu, 1206 Geneva, Switzerland  \n* Correspondence: [afriedlaender@beaulieu.ch](afriedlaender@beaulieu.ch)  \nSimple Summary: Advances in next-generation sequencing have initiated a paradigm shift in cancer treatment, transitioning from traditional, organ-specific protocols to precision medicine. However, interpreting the clinical implications of an ever-growing catalog of genetic mutations remains challenging. This review explores the direct connections between genetic alterations and targeted therapies, addressing key genetic factors, the challenges in clinical application and research, and strategies for maximizing the therapeutic impact of these treatments.  \nAbstract: Advances in next-generation sequencing (NGS) have catalyzed a paradigm shift in cancer treatment, steering the focus from conventional, organ-specific protocols to precision medicine. Emerging targeted therapies offer a cutting-edge approach to cancer treatment, while companion diagnostics play an essential role in aligning therapeutic choices with specific molecular changes identified through NGS. Despite these advances, interpreting the clinical implications of a rapidly expanding catalog of genetic mutations remains a challenge. The selection of therapies in the presence of multiple mutations requires careful clinical judgment, supported by quality-centric genomic testing that emphasizes actionable mutations. Molecular tumor boards can play an increasing role in assimilating genomic data into clinical trials, thereby refining personalized treatment approaches and improving patient outcomes.  \nKeywords: precision medicine; oncogenic drivers; precision oncology; personalized medicine; oncogenic alterations; driver mutations  \n1. Introduction  \nThe advancement in cancer genomics, particularly the widespread adoption of nextgeneration sequencing (NGS) in the past two decades, has been instrumental in identifying genetic mutations responsible for cancer. This has enabled the development of therapies that intervene in the resulting aberrant signaling pathways. NGS is now integral to cancer diagnostics, aiding in the determination of mutations for selecting targeted treatments, prognostication, and other clinical decisions. Unlike conventional chemotherapy that non-selectively targets rapidly dividing cells, targeted therapies act on specific proteins resulting from cancer-causing mutations, offering greater efficacy and fewer side effects.  \nA landmark in targeted therapy was the discovery of the BCR-ABL fusion gene in chronic myelogenous leukemia (CML) and the subsequent development of imatinib, a BCR-ABL inhibitor [1] . This success has led to the Food and Drug Administration (FDA) approval of various targeted therapies, with many others currently under investigation.  \nMutations in oncogenes can result in a variant protein or cau","cbCaih0z4sd6QyXY","https://ap.wps.com/l/cbCaih0z4sd6QyXY","pdf",1531343,30,"English","# 1. Introduction\n# 2. Genomics, Proteomics, and the Use of Next Generation Sequencing","[{\"question\":\"How has next-generation sequencing changed cancer treatment?\",\"answer\":\"NGS enables identification of cancer-driving mutations and supports precision medicine by guiding targeted therapy selection rather than relying only on conventional organ-specific approaches.\"},{\"question\":\"What role do companion diagnostics play in targeted therapy?\",\"answer\":\"Companion diagnostics align therapeutic decisions with specific molecular changes identified through NGS, helping ensure that treatment matches actionable genetic alterations.\"},{\"question\":\"Why is interpreting genetic mutation catalogs clinically challenging?\",\"answer\":\"Clinical interpretation is difficult because the catalog of genetic mutations is rapidly expanding and patients may carry multiple mutations, requiring careful judgment and quality-focused testing.\"}]","Advances in Personalized Oncology | PDF",1790033341,76,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4305272d86a86317ca05e44e6333b6db.webp",983,1390,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9043d5af4aff4394f1f3775a3625334.webp",982,1388,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9c439d6fd30ad51231f2965be60740f.webp",981,1387,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84370c8cf985bcfdad5818da44ea8096.webp",980,1385,{"code":4,"msg":82,"data":117},[118,122,126,130,135,139,144,146,151,154,158],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":136,"show_sort_weight":137,"slug":138},"Technology",50,"technology",{"id":140,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":92,"slug":145},"research-report",{"id":147,"doc_module":4,"doc_module_name":25,"category_name":148,"show_sort_weight":149,"slug":150},9,"Religion & Spirituality",20,"religion-spirituality",{"id":149,"doc_module":4,"doc_module_name":25,"category_name":152,"show_sort_weight":149,"slug":153},"World Cup","world-cup",{"id":155,"doc_module":4,"doc_module_name":25,"category_name":156,"show_sort_weight":155,"slug":157},10,"Lifestyle","lifestyle",{"id":159,"doc_module":4,"doc_module_name":25,"category_name":160,"show_sort_weight":131,"slug":161},19,"General","general"]